Marion Merrell Dow/Affymax
Executive Summary
Enter strategic alliance for drug discovery, initially targeted at arthritis, cancer, and autoimmune disease, the companies announced June 13. In return for an undisclosed equity investment, milestone payments, and royalties on any resulting products, Palo Alto-based Affymax will perform drug discovery and development work using its VLSIPS screening technology. MMD indicated that, in the future, the disease targets may be expanded to include respiratory, cardiovascular and gastrointestinal products, although terms would have to be renegotiated. The deal is the first for Affymax, a privately-held startup founded in 1988 by Alejandro Zaffaroni, PhD, the founder of Alza, Syntex and DNAX.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth